Verdict Hospital is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



PET/CT: Positive Partnership

Figure 3.An 18-year-old female with a history of extensive Hodgkin’s lymphoma who had serial PET/CT exams. A. The initial imaging shows intense FGD activity within bulky mediastinal lymphadeopathy. B. Follow-up imaging midway through treatment shows dramatic interval reduction in lymphadenopathy size and absence of FDG activity. C. Patient is one year post-therapy with residual anatomic tissue but no metabolic activity and no evidence of disease recurrence.



Go Top